si-b003
mAbexperimentalMulti-specific
Clinical trial activity
11 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2020 (NCT04606472)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06668961 | Phase 2 | Nov 30, 2024 | Baili Pharmaceutical Group |
| NCT05956587 | Phase 2 | Jan 31, 2024 | Baili Pharmaceutical Group, Sun Yat-Sen University |
| NCT06042894 | Phase 2 | Dec 12, 2023 | Baili Pharmaceutical Group, Fudan University |
| NCT05965856 | Phase 2 | Dec 11, 2023 | Baili Pharmaceutical Group, Fudan University |
| NCT06008054 | Phase 2 | Nov 16, 2023 | Baili Pharmaceutical Group, Peking University |
| NCT05924841 | Phase 2 | Nov 10, 2023 | Baili Pharmaceutical Group, Jilin Provincial Tumor Hospital |
| NCT05990803 | Phase 2 | Nov 6, 2023 | Baili Pharmaceutical Group, Chinese Academy of Medical Sciences |
| NCT05949606 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2023 | Baili Pharmaceutical Group, Huazhong University of Science and Technology |
| NCT06006169 | Phase 2 | Oct 20, 2023 | Baili Pharmaceutical Group, Fudan University |
| NCT05668858 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | Baili Pharmaceutical Group, Shanghai Oriental Hospital |
| NCT04606472 | Phase 1 | Oct 31, 2020 | Baili Pharmaceutical Group, Chinese Academy of Medical Sciences, SystImmune Inc. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 11 | 11 | 2 | 2020 |
| Fudan University | Academic/Hospital | 3 | 0 | 1 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Jilin Provincial Tumor Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Shanghai Oriental Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| SystImmune Inc. | For profit | 1 | 0 | 1 | 2020 |
9 organizations
Page 1 / 1